Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Menzl, I; Zhang, T; Berger-Becvar, A; Grausenburger, R; Heller, G; Prchal-Murphy, M; Edlinger, L; Knab, VM; Uras, IZ; Grundschober, E; Bauer, K; Roth, M; Skucha, A; Liu, Y; Hatcher, JM; Liang, Y; Kwiatkowski, NP; Fux, D; Hoelbl-Kovacic, A; Kubicek, S; Melo, JV; Valent, P; Weichhart, T; Grebien, F; Zuber, J; Gray, NS; Sexl, V.
A kinase-independent role for CDK8 in BCR-ABL1+ leukemia.
Nat Commun. 2019; 10(1): 4741
Doi: 10.1038/s41467-019-12656-x
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Edlinger Leo
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Cyclin-dependent kinases (CDKs) are frequently deregulated in cancer and represent promising drug targets. We provide evidence that CDK8 has a key role in B-ALL. Loss of CDK8 in leukemia mouse models significantly enhances disease latency and prevents disease maintenance. Loss of CDK8 is associated with pronounced transcriptional changes, whereas inhibiting CDK8 kinase activity has minimal effects. Gene set enrichment analysis suggests that the mTOR signaling pathway is deregulated in CDK8-deficient cells and, accordingly, these cells are highly sensitive to mTOR inhibitors. Analysis of large cohorts of human ALL and AML patients reveals a significant correlation between the level of CDK8 and of mTOR pathway members. We have synthesized a small molecule YKL-06-101 that combines mTOR inhibition and degradation of CDK8, and induces cell death in human leukemic cells. We propose that simultaneous CDK8 degradation and mTOR inhibition might represent a potential therapeutic strategy for the treatment of ALL patients.
- Find related publications in this database (using NLM MeSH Indexing)
- Animals - administration & dosage
- Cell Line, Tumor - administration & dosage
- Cell Survival - drug effects, genetics
- Cyclin-Dependent Kinase 8 - antagonists & inhibitors, genetics, metabolism
- Disease Models, Animal - administration & dosage
- Fusion Proteins, bcr-abl - antagonists & inhibitors, genetics, metabolism
- Humans - administration & dosage
- Mice, Inbred C57BL - administration & dosage
- Mice, Inbred NOD - administration & dosage
- Mice, Knockout - administration & dosage
- Mice, SCID - administration & dosage
- Mice, Transgenic - administration & dosage
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy, genetics, metabolism
- Protein Kinase Inhibitors - pharmacology
- Signal Transduction - drug effects, genetics
- Small Molecule Libraries - pharmacology
- TOR Serine-Threonine Kinases - antagonists & inhibitors, genetics, metabolism